US5049221055
© PR Newswire
29.04.2024
LH
LISTED
NYSE
Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B
News Preview
Assay expands company's leadership in precision medicine and cell and gene therapy
BURLINGTON, N.C., April 29, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the U.S. Food and Drug Administration (FDA) has approved its nAbCyte™ Anti-AAVRh74var HB-FE Assay, a companion...
Themefolio
Profiler
Peergroup
© PR Newswire
25.04.2024
LH
LISTED
NYSE
Labcorp Announces 2024 First Quarter Results
News Preview
Updates Full-Year Guidance
Results from Continuing Operations for first quarter 2024 versus last year:Revenue: $3.18 billion versus $3.04 billion or up 4.6% | Base Business grew 6.7%Diluted EPS: $2.69 versus $2.34Adjusted EPS: $3.68 versus $3.46Full-Year 2024 Guidance: Raised midpoint and narrowed range of adjusted EPS to $14.45 to $15.35; Free C...
Themefolio
Profiler
Peergroup
© PR Newswire
25.04.2024
LH
LISTED
NYSE
Invitae Enters into Agreement with Labcorp for Sale of Business
News Preview
– Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals –
– $239 Million Cash Bid Includes Acquisition of Substantially All of the Company's Assets, Ensuring Business Continuity for Customers, Partners and Employees –
SAN FRANCISCO, April 24, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leadi...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
15.04.2024
LH
LISTED
NYSE
Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw
News Preview
Innovative GFAP blood biomarker test expands Labcorp's portfolio of tests for diseases including Alzheimer's disease, multiple sclerosis, glioblastoma and brain injuries
BURLINGTON, N.C., April 15, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the availability of the...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
11.04.2024
LH
LISTED
NYSE
Labcorp Declares Quarterly Dividend
News Preview
BURLINGTON, N.C., April 11, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on June 12, 2024, to stockholders of record as of the close of business...
Themefolio
Profiler
Peergroup
© PR Newswire
10.04.2024
LH
LISTED
NYSE
Labcorp Receives FDA Emergency Use Authorization for Mpox PCR Test Home Collection Kit
News Preview
The first at-home mpox testing kit provides patients with convenience and privacy to test for mpox, supports physicians in detection and treatment
BURLINGTON, N.C., April 10, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the U.S. Food and Drug Administration (FDA) has...
Themefolio
Profiler
Peergroup
© PR Newswire
08.04.2024
LH
LISTED
NYSE
Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs
News Preview
Portfolio expansion solidifies company's commitment to advancing cancer research and patient care
BURLINGTON, N.C., April 8, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the strategic expansion of its precision oncology portfolio, solidifying its commitment to advanc...
Themefolio
Profiler
Peergroup
© PR Newswire
05.04.2024
LH
LISTED
NYSE
Labcorp Launches Labcorp® Plasma Detect™ Extending Leadership into Molecular Residual Disease (MRD) Clinical Research
News Preview
Labcorp Plasma Detect is the first clinically validated, whole-genome sequencing MRD solution for early-stage colon cancer
BURLINGTON, N.C., April 5, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp® Plasma Detect™, the first clinically validated, t...
Themefolio
Profiler
Peergroup
© PR Newswire
02.04.2024
LH
LISTED
NYSE
Labcorp to Present Diverse Portfolio of Precision Oncology Research at the Annual Meeting of the American Association for Cancer Research
News Preview
Researchers to present on topics ranging from molecular residual disease and immunotherapy to whole-genome sequencing
BURLINGTON, N.C., April 2, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will present abstracts in the areas of immunology, cellular biology, genomics and liquid biop...
Themefolio
Profiler
Peergroup
© PR Newswire
29.03.2024
LH
LISTED
NYSE
The Prelude Network® Names Labcorp Its Preferred Genetic Carrier Screening Lab
News Preview
Expanded partnership to help increase patient access to critical genetic screening services including genetic counseling and test result turnaround time
HOUSTON, March 29, 2024 /PRNewswire/ -- The Prelude Network® (Prelude), the largest network of fertility clinics in North America, announced today an expansion of its partnership with Labcorp (N...
Themefolio
Profiler
Peergroup
© PR Newswire
27.03.2024
LH
LISTED
NYSE
Labcorp to Announce First Quarter Financial Results on April 25, 2024
News Preview
BURLINGTON, N.C., March 27, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2024 before the market opens on Thursday, April 25, 2024. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discu...
Themefolio
Profiler
Peergroup
© PR Newswire
20.03.2024
LH
LISTED
NYSE
Labcorp Launches pTau217 Blood Biomarker Test to Accelerate Path to Diagnosis of Alzheimer's Disease and Support Clinical Trials
News Preview
Addition of pTau217 test further expands the company's leadership in testing options for Alzheimer's disease to improve patient care
BURLINGTON, N.C., March 20, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch and immediate availability of its test to identif...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
16.03.2024
LH
LISTED
NYSE
Labcorp Presents New Research Demonstrating Clinical Impact of Precision Diagnostics in Guiding Biomarker-targeted Therapies for Patients with Epithelial Ovarian Cancer
News Preview
Outcomes point to value of biomarker testing in addressing testing gaps in clinical practice
BURLINGTON, N.C., March 16, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today presented the results from two studies at the 2024 SGO Annual Meeting on Women's Cancer. The studies demonstrat...
Themefolio
Profiler
Peergroup
© PR Newswire
07.03.2024
LH
LISTED
NYSE
Labcorp Launches Weight Loss Management Testing Solutions
News Preview
New offering to support individuals and physicians with accessible and convenient testing options to guide weight loss management decisions and treatments
BURLINGTON, N.C., March 7, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the introduction of its Weight Loss Mana...
Themefolio
Profiler
Peergroup
© PR Newswire
15.02.2024
LH
LISTED
NYSE
Labcorp Announces 2023 Fourth Quarter and Full Year Results
News Preview
Company Provides 2024 Guidance
Results from Continuing Operations for the fourth quarter and full year versus last year:Revenue: Q4 of $3.03 billion vs $2.93 billion; Full year of $12.16 billion vs $11.86 billionDiluted EPS: Q4 of $(1.95) vs $0.42 ; Full year of $4.33 vs $10.94Adjusted EPS: Q4 of $3.30 vs $3.05 ; Full year of $13.56 vs $16.66Free...
Themefolio
Profiler
Peergroup
© PR Newswire
01.02.2024
LH
LISTED
NYSE
Labcorp Named One of the World's Most Admired Companies™ by FORTUNE® Magazine
News Preview
BURLINGTON, N.C., Feb. 1, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, has once again been named to FORTUNE® magazine's list of the World's Most Admired Companies™, a recognition of the most respected and reputable companies globally....
Themefolio
Profiler
Peergroup
© PR Newswire
31.01.2024
LH
LISTED
NYSE
Labcorp Launches New Test for Risk Assessment and Prognosis of Severe Preeclampsia in Pregnant Women
News Preview
B•R•A•H•M•S™ sFlt-1/PlGF KRYPTOR™ Test System is available through physicians and is the first FDA-cleared biomarker test to aid in the risk assessment of progression to preeclampsia with severe features, a leading cause of maternal and fetal mortality in the U.S.1
BURLINGTON, N.C., Jan. 31, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leade...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2024
LH
LISTED
NYSE
Labcorp to Announce Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024
News Preview
BURLINGTON, N.C., Jan. 16, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth quarter and full year 2023 before the market opens on Thursday, February 15, 2024. The company will host a conference call and webcast beginning at 9 a.m. ET tha...
Themefolio
Profiler
Peergroup
© PR Newswire
12.01.2024
LH
LISTED
NYSE
Labcorp Declares Quarterly Dividend
News Preview
BURLINGTON, N.C., Jan. 12, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 13, 2024, to stockholders of record as of the close of business on February 27, 2024....
Themefolio
Profiler
Peergroup
© PR Newswire
10.01.2024
LH
LISTED
NYSE
Labcorp and Hawthorne Effect Collaborate to Bring Clinical Trials Directly to Patients and Investigators in Local Communities
News Preview
Collaboration Aims to Improve Patient Experience, Accessibility and Efficiency in Decentralized Clinical Trials
BURLINGTON, N.C. and LAFAYETTE, Calif., Jan. 10, 2024 /PRNewswire/ -- Labcorp, a global leader of innovative and comprehensive laboratory services, and Hawthorne Effect, Inc., a complete clinical trials solution integrating technology, ...
Themefolio
Profiler
Peergroup
© PR Newswire
02.01.2024
LH
LISTED
NYSE
Labcorp to Speak at the 42nd Annual J.P. Morgan Healthcare Conference
News Preview
BURLINGTON, N.C., Jan. 2, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team will participate in a fireside chat at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 9 at 4:30 p.m. (PT)....
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
